Abstract: A triazolopyridine compound represented by formula I-a and a preparation method therefor, a pharmaceutical composition containing the compound, and a use of the compound as an LPA1 receptor inhibitor in the treatment of LPA1 related diseases.

Abstract: A plate shaped heater for heating a heat shrink tube on a cable includes a housing, multiple heating tubes arranged within the housing, and a heating wire arranged in the multiple heating tubes. The housing defines opposite ends in its longitudinal direction. The heating tubes extend along a transverse direction of the housing and are arranged in a row along the longitudinal direction of the housing. An arrangement density of the heating tubes in two end regions proximate two ends of the housing is greater than an arrangement density of the heating tubes in a middle region between the two end regions of the housing.

Abstract: A technique for performing ray tracing operations is provided.

Abstract: The present disclosure provides a headphone including a sound production component and an ear hook. The ear hook and the sound production component form a first projection on a user's sagittal plane. In a non-wearing state, an inner contour, a first end contour, a second end contour of the first projection, and a tangent segment connecting the first end contour and the second end contour jointly define a first closed curve. A first area of the first closed curve ranges 300 mm2-500 mm2. A portion of the inner contour corresponding to the ear hook includes a first curve. The first curve has an extremum point in a first direction perpendicular to a long axis direction of a projection of the sound production component, the extremum point is located behind a projection point of an upper vertex of the ear hook on the sagittal plane.

Abstract: Disclosed herein are methods of treating/inhibiting/reducing a non-immunogenic cancer in a subject or inducing blockade inhibitor susceptibility (such as, for example, PD-1/PDLI, CTLA-4/B7-1/2, and/or CD47/SIRPa inhibitor susceptibility) in a tumor in a subject with a cancer, said methods comprising administering to the subject a hydrogel matrix comprising a chemotherapeutic agent (including, but not limited to gemcitabine) and a blockade inhibitor (including, but not limited to a PD-1/PD-LI blockade inhibitor, such as, for example nivolumab, pembrolizumab, pidilizumab, atezolizumab, avelumab, durvalumab, and BMS-936559; a CTLA-4/B7-1/2 inhibitor such as, for example, Ipilimumab; and/or a CD47/SIRPa inhibitor such as, for example Hu5F9-G4, CVI, B6H12, 2D3, CC-90002, and TTI-621).

Abstract: Methods, systems, and devices for a sorted change log for physical page table compression are described. A mapping between a logical address and a physical address may be stored in a change log buffer. The mapping may be stored at a location of the change log buffer based on the logical address of the mapping relative to logical addresses of other mappings stored in the change log buffer. Based on storing mappings in the change log buffer based on logical addresses of the mappings, a set of mappings in the change log may include a set of sequentially-indexed logical addresses. A compressed entry for a logical-to-physical table may be generated based on the set of mappings.

Abstract: Methods, systems, and devices for logical-to-physical (L2P) mapping compression techniques are described. A memory system may use an L2P mapping to map logical addresses to physical addresses of the memory system. The L2P mapping may be a hierarchical L2P mapping divided into multiple levels or subsets that are used to identify a physical address corresponding to a logical address. The memory system may write data to a set of physical addresses that are consecutively indexed and may set a flag in an entry of a second-level of the L2P mapping (e.g., of a three-level L2P mapping) to indicate that the entry is associated with a starting physical address of the consecutively indexed physical addresses. The memory system may subsequently read the data starting at the starting physical address based on the flag (e.g., bypassing reading an entry of a lowest-level of the L2P mapping to determine the physical address).

Abstract: A minimally invasive glucose-responsive colloidal crystal microneedle (GCC-MN) patch is disclosed for naked-eye glucose monitoring. The (GCC-MN) patch is designed with a resin or polymeric core to mechanically support a shell of glucose-responsive colloidal crystal material for glucose sensing and reporting of glucose concentrations or concentration changes. The GCC-MN patch could translate the glucose concentrations into naked-eye distinguishable color changes within about 5 min, and such glucose responsiveness is reversible. Demonstrated in a type 1 diabetic mouse model, the interstitial fluid extraction, glucose sensing, and resulting glucose-relevant color display procedures are simultaneously achieved with this GCC-MN patch.

Abstract: A two-terminal resistive switching device (TTRSD) such as a non-volatile two-terminal memory device or a volatile two-terminal selector device can be formed according to a manufacturing process. The process can include forming an etch stop layer that is made of aluminum and can include forming a buffer layer below the etch stop layer and/or between the etch stop layer and a top electrode of the TTRSD.

Abstract: Disclosed herein are self-degradable microneedle devices for the controlled-release of an immunotherapeutic agent. Also disclosed are methods for treating a disease (for example, cancer) using a self-degradable microneedle patch for the sustained delivery of an immunotherapeutic agent (for example, a PD1 antibody).

Abstract: Disclosed herein is a glucose-responsive insulin delivery system based on the interaction between the glucose-modified insulin and glucose transporters (GLUTs) on erythrocytes (or red blood cells, RBCs). After being conjugated with glucose, insulin can efficiently bind to RBC membranes. The binding is reversible in the setting of hyperglycemia, resulting in fast release of insulin and subsequent drop of blood glucose (BG) level in vivo. In some embodiments, the delivery vehicle can include: 1) intravenously injectable polymeric nanoparticles (˜100 nm in diameter) coated with RBC membrane and loaded with glucose-modified insulin and/or 2) painless microneedle (MN) patches loaded with the complex of GLUT and glucose-modified insulin.

Abstract: A multiplication unit includes first, second, third and fourth receiving terminals, arithmetic units and multiplexers. In complex number mode, the first and second receiving terminals receive a real part value and an imaginary part value of a first complex number, respectively, whereas the third and fourth receiving terminals receive a real part value and an imaginary part value of a second complex number, respectively. In modulus mode, the first and third receiving terminals receive first and second integers, respectively. The multiplexers gate the arithmetic units to perform a complex number multiplication operation according to the first and second complex numbers to generate a third complex number in complex number mode and perform a modulus multiplication operation according to the first and second integers and a predetermined modulus to generate a third integer in modulus mode.

Abstract: A method for drivable area detection and autonomous obstacle avoidance of unmanned haulage equipment in deep confined spaces is disclosed, which includes the following steps: acquiring 3D point cloud data of a roadway; computing a 2D image drivable area of the coal mine roadway; acquiring a 3D point cloud drivable area of the coal mine roadway; establishing a 2D grid map and a risk map, and performing autonomous obstacle avoidance path planning by using a particle swarm path planning method designed for deep confined roadways; and acquiring an optimal end point to be selected of a driving path by using a greedy strategy, and enabling an unmanned auxiliary haulage vehicle to drive according to the optimal end point and an optimal path. Images of a coal mine roadway are acquired actively by use of a single-camera sensor device.

Abstract: The present invention provides a mRNA composition for microneedle administration and its application. The composition includes an aqueous phase solution and a lipid solution, wherein the lipid solution encapsulates the substance in the aqueous phase solution to form lipid nanoparticles (LNPs), and the aqueous phase solution includes mRNA encoding the corresponding protein and a buffer. It was found that an improved buffer pH could substantially increase the drug loading capacity of LNPs, and reduce the use level of composition and excipients and the dose for microneedle administration with less toxic side effects and better therapeutic effects, and the microneedle administration technology could achieve increased effective expression, decreased expression in the liver, and prolonged in vivo expression of mRNA composition, and increased antibody titer in response to low-dose mRNA in vivo. The present invention really realizes microneedle intradermal administration of mRNA composition.

Abstract: Embodiments of the present disclosure relate generally to photoimmunotherapy for treating cancer. More particularly, the present disclosure provides photo-responsive dermal applicators that use transdermal microneedle arrays to administer an immunogenic composition and a photo-sensitive biological pigment to a subject to treat and/or prevent cancer. Photo-responsive dermal applicators of the present disclosure provide the ability to target cancerous tumors in a manner that is safer and less invasive than conventional means.

Abstract: A glucose-responsive therapeutic material demonstrates consistent and slow basal insulin release under a normoglycemic condition and accelerated insulin release in response to hyperglycemia. The therapeutic material uses a poly-L-lysine-derived polymer (PLL) modified with 4-carboxy-3-fluorophenylboronic acid (FPBA) that forms a polymer-insulin complex for glucose-stimulated insulin delivery. The release profile of the therapeutic material may be adjusted or tuned by altering the ratio of modified polymer (PLL-FPBA) to insulin in the therapeutic material, FPBA-modification degree of polymer, and altering the molecular weight of the polymer. The therapeutic material may be delivered to a mammalian subject using a delivery device (e.g., subcutaneous injection).

Abstract: A composition comprising an insulin-polymer conjugate and an insulin aptamer-glucagon conjugate is described. Depending upon the amount of insulin in the environment surrounding the composition, the insulin aptamer of the insulin aptamer-glucagon conjugate can bind to insulin in the insulin-polymer conjugate to form a non-covalent conjugate. When the amount of insulin in the surrounding environment rises, the insulin aptamer-glucagon conjugate can be released. Thus, the composition can be used to deliver glucagon in an insulin responsive manner. The composition can be loaded into microneedles, for example, to prepare microneedle arrays for skin patches. Methods of delivering glucagon to a subject are also described.

Abstract: The disclosure discloses a global shutter CMOS image sensor, which adopts non-uniform storage diffusion region doping to reduce the junction leakage at storage points, so as to ensure that with the increase of the depth of photodiodes and the increase of pixels, all carriers in rows read subsequently can be transferred to storage diffusion regions, the loss of the carriers in the storage diffusion regions is not caused when a global shutter transistor is turned on, and the carriers can be completely transferred from the storage diffusion regions to floating diffusion regions through second transfer transistors even if the number of rows of pixel units increases during reading-out row by row. The disclosure further discloses a method for making the global shutter CMOS image sensor.

Abstract: Provided herein are methods and compositions related to cryo-shocked cells useful as therapeutic agents. The cryo-shocked cells may be formulated as a vaccine. Disclosed are methods of preparing dead cryo-shocked cells. Disclosed are also methods of treating or preventing cancer, comprising administering the cryo-shocked cells. Further, methods for delivering a drug to a target tissue of a patient are disclosed.

Abstract: Disclosed are compositions and methods for microneedle patches comprising diblock copolymer micelles designed for pH cascade and H2O2 triggered insulin delivery.